Page 20«..10..19202122..3040..»

AB2 Bio to Participate in Orphan Disease Panel Discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

By Dr. Matthew Watson

Investors can pre-register for the event here

Read the original post:
AB2 Bio to Participate in Orphan Disease Panel Discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

To Read More: AB2 Bio to Participate in Orphan Disease Panel Discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
categoriaGlobal News Feed commentoComments Off on AB2 Bio to Participate in Orphan Disease Panel Discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event | dataJanuary 5th, 2021
Read All

Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

By Dr. Matthew Watson

LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on-demand starting at 8:00 AM ET on Monday, January 11, 2021.

Originally posted here:
Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

To Read More: Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
categoriaGlobal News Feed commentoComments Off on Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference | dataJanuary 5th, 2021
Read All

Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine

By Dr. Matthew Watson

PRESS RELEASE

Read this article:
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine

To Read More: Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
categoriaGlobal News Feed commentoComments Off on Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine | dataJanuary 5th, 2021
Read All

Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference

By Dr. Matthew Watson

PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 10:50 a.m. ET, and host investor meetings.

Read more from the original source:
Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference

To Read More: Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference | dataJanuary 3rd, 2021
Read All

Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market

By Dr. Matthew Watson

Company Receives additional 180-day grace period, until June 28, 2021, to satisfy the $1.00 bid price requirement to maintain Nasdaq listing

Read the original:
Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market

To Read More: Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market
categoriaGlobal News Feed commentoComments Off on Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market | dataJanuary 3rd, 2021
Read All

VAXIL Provides Update on USAMRIID and Oral Experiments

By Dr. Matthew Watson

NESS-ZIONA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that further to our press release dated December 3, 2020, in respect to our cooperative research and development agreement (CRADA) with US Army Medical Research Institute of Infectious Diseases (“USAMRIID”), the mice have received two of the three scheduled vaccinations. The third and final vaccine is scheduled to be administered later this week. USAMRIID reports that the mice appear to be fine having responded normally to the injections administered to date and that the experiment is proceeding on schedule. The Company expects that the mice will be “challenged” with the COVID-19 virus in mid-January 2021, after having had the chance to develop an immune response. Vaxil expects to provide a further update at the beginning of February 2021.

Read the original:
VAXIL Provides Update on USAMRIID and Oral Experiments

To Read More: VAXIL Provides Update on USAMRIID and Oral Experiments
categoriaGlobal News Feed commentoComments Off on VAXIL Provides Update on USAMRIID and Oral Experiments | dataJanuary 3rd, 2021
Read All

Lui Franciosi Reviewing the Use of Sugar-Based Molecules as Potential Treatments for COVID-19

By Dr. Matthew Watson

VANCOUVER, British Columbia, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Lui Franciosi is pleased to announce that Franciosi Consulting Ltd. will be reviewing the pharmacological feasibility of using specific glycosaminoglycans (GAGs) for the treatment of SARS-CoV-2, i.e., COVID-19. GAGs are long linear polysaccharides consisting of repeating disaccharide units (i.e., two-sugar units) that participate in many biological processes, in particular, cell signalling and development, angiogenesis, anti-coagulation, tumour progression, axonal growth and metastasis. Their large structural diversity makes them useful in the discovery of new drugs. The clinically best-known GAG is heparin, which is an anticoagulant used for the treatment of thrombophlebitis, embolism, and thrombosis. It also has anti-inflammatory activity. However, its major side effects are bleeding and bruising, especially in the elderly. From the COVID-19 medical literature, the virus appears to cause increased activation of cells that are involved with the clotting and inflammatory processes. This may lead to an increased risk of blood clots and lung inflammation. Currently, there are clinical studies of heparin underway looking at its benefits in COVID-19 patients, but bleeding is still a major issue. Therefore, there is a need to come up with a better heparin-like molecule which is anti-inflammatory but with minimal anticoagulant effects.

More here:
Lui Franciosi Reviewing the Use of Sugar-Based Molecules as Potential Treatments for COVID-19

To Read More: Lui Franciosi Reviewing the Use of Sugar-Based Molecules as Potential Treatments for COVID-19
categoriaGlobal News Feed commentoComments Off on Lui Franciosi Reviewing the Use of Sugar-Based Molecules as Potential Treatments for COVID-19 | dataJanuary 3rd, 2021
Read All

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

By Dr. Matthew Watson

Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number 10,874,713 entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent & Trade Mark Office.

Read this article:
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

To Read More: Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
categoriaGlobal News Feed commentoComments Off on Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor | dataJanuary 3rd, 2021
Read All

Eve & Co Announces Share Consolidation

By Dr. Matthew Watson

TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Eve & Co. Incorporated (TSXV: EVE) (OTCQX: EEVVF) (the “Company” or “Eve & Co”) announces that it has filed articles of amendment to consolidate the Company’s issued and outstanding common shares on the basis of one (1) new common share for every ten (10) existing common shares (the “Consolidation”).

See more here:
Eve & Co Announces Share Consolidation

To Read More: Eve & Co Announces Share Consolidation
categoriaGlobal News Feed commentoComments Off on Eve & Co Announces Share Consolidation | dataJanuary 3rd, 2021
Read All

Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets

By Dr. Matthew Watson

BRIDGEWATER, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) regarding the Company's New Drug Application (“NDA”) seeking approval for the investigational agent arbaclofen extended release ("ER") tablets to treat spasticity resulting from multiple sclerosis.

See original here:
Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets

To Read More: Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets
categoriaGlobal News Feed commentoComments Off on Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets | dataJanuary 3rd, 2021
Read All

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

By Dr. Matthew Watson

TORONTO, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. John Fahy, MD, MSc, as a Scientific and Clinical advisor to the Company to assist in the expansion and the analysis of the clinical data on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

Continued here:
Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

To Read More: Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study
categoriaGlobal News Feed commentoComments Off on Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study | dataJanuary 3rd, 2021
Read All

Total number of shares and voting rights in Zealand Pharma at December 31, 2020

By Dr. Matthew Watson

Company announcement – No. 64 / 2020

Here is the original post:
Total number of shares and voting rights in Zealand Pharma at December 31, 2020

To Read More: Total number of shares and voting rights in Zealand Pharma at December 31, 2020
categoriaGlobal News Feed commentoComments Off on Total number of shares and voting rights in Zealand Pharma at December 31, 2020 | dataJanuary 3rd, 2021
Read All

Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)

By Dr. Matthew Watson

Press Release

Read more here:
Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)

To Read More: Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)
categoriaGlobal News Feed commentoComments Off on Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC) | dataJanuary 3rd, 2021
Read All

Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia

By Dr. Matthew Watson

THE WOODLANDS, Texas, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of post-herpetic neuralgia. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1).

Follow this link:
Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia

To Read More: Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
categoriaGlobal News Feed commentoComments Off on Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia | dataJanuary 3rd, 2021
Read All

Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete…

By Dr. Matthew Watson

MIRAMAR, Fla., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that its majority owned public entity, NuGenerex Immuno-Oncology, Inc. (NGIO), has filed for and expects to receive a trademark for The Complete Vaccine™. A complete vaccine is designed to regulate the immune system to provide a targeted, neutralizing antibody response without generating off-target, non-neutralizing antibodies that can lead to antibody dependent enhancement of disease (ADE); further a complete vaccine should activate the appropriate T cell responses to yield long-term immune memory without activating detrimental Th2 responses that have been associated with immune-related complications of COVID-19 disease.

Continue reading here:
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete...

To Read More: Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete…
categoriaGlobal News Feed commentoComments Off on Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete… | dataJanuary 3rd, 2021
Read All

Avicanna Announces Exercise and Closing of Over-Allotment Option

By Dr. Matthew Watson

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Follow this link:
Avicanna Announces Exercise and Closing of Over-Allotment Option

To Read More: Avicanna Announces Exercise and Closing of Over-Allotment Option
categoriaGlobal News Feed commentoComments Off on Avicanna Announces Exercise and Closing of Over-Allotment Option | dataJanuary 3rd, 2021
Read All

Tauriga Sciences Inc. Approved to be Corporate Exhibitor at 2021 CTIC Capital Pre-J.P. Morgan Healthcare Investment Summit January 9th-10th, 2021

By Dr. Matthew Watson

The Company Will Exhibit Through a Virtual Booth to Present its Products, Product Lines, and Business Initiatives to a Broad Array of Top Tier Institutional Biotech Investors

Read the original post:
Tauriga Sciences Inc. Approved to be Corporate Exhibitor at 2021 CTIC Capital Pre-J.P. Morgan Healthcare Investment Summit January 9th-10th, 2021

To Read More: Tauriga Sciences Inc. Approved to be Corporate Exhibitor at 2021 CTIC Capital Pre-J.P. Morgan Healthcare Investment Summit January 9th-10th, 2021
categoriaGlobal News Feed commentoComments Off on Tauriga Sciences Inc. Approved to be Corporate Exhibitor at 2021 CTIC Capital Pre-J.P. Morgan Healthcare Investment Summit January 9th-10th, 2021 | dataJanuary 3rd, 2021
Read All

Teligent, Inc. Announces Third Quarter 2020 Results

By Dr. Matthew Watson

BUENA, N.J., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020.

Here is the original post:
Teligent, Inc. Announces Third Quarter 2020 Results

To Read More: Teligent, Inc. Announces Third Quarter 2020 Results
categoriaGlobal News Feed commentoComments Off on Teligent, Inc. Announces Third Quarter 2020 Results | dataJanuary 3rd, 2021
Read All

Draft Top Tool Reviews – Go Topless! – Product Review by Mike Vaughn

By Dr. Matthew Watson

Read the rest here:
Draft Top Tool Reviews - Go Topless! – Product Review by Mike Vaughn

To Read More: Draft Top Tool Reviews – Go Topless! – Product Review by Mike Vaughn
categoriaGlobal News Feed commentoComments Off on Draft Top Tool Reviews – Go Topless! – Product Review by Mike Vaughn | dataJanuary 3rd, 2021
Read All

Vaxil’s Annual and Special Shareholders Meeting and Update on Exercise of Warrants

By Dr. Matthew Watson

Not for distribution by US newswire or in United States

Continued here:
Vaxil’s Annual and Special Shareholders Meeting and Update on Exercise of Warrants

To Read More: Vaxil’s Annual and Special Shareholders Meeting and Update on Exercise of Warrants
categoriaGlobal News Feed commentoComments Off on Vaxil’s Annual and Special Shareholders Meeting and Update on Exercise of Warrants | dataJanuary 3rd, 2021
Read All

Page 20«..10..19202122..3040..»